Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060613 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Obsidian Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 9
- Study locations
NCT06060613: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Obsidian Therapeutics.
NCT06060613 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Obsidian Therapeutics. The registered enrollment target is 52 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06060613, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Obsidian Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Primary Outcome
• Incidence of dose-limiting toxicities (DLTs) during the first 28 days after OBX-115 infusion (Phase 1).
Conditions Studied
Interventions
- BIOLOGICAL OBX-115
Study Locations (9)
California
- The Angeles Clinic and Research Institute (Melanoma) - Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) - Los Angeles
- Stanford Cancer Institute (Melanoma/NSCLC) - Stanford
Florida
- Orlando Health Cancer Institute (Melanoma/NSCLC) - Orlando
Kentucky
- James Graham Brown Cancer Center (Melanoma/NSCLC) - Louisville
New York
- Memorial Sloan Kettering (Melanoma/NSCLC) - New York
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Allegheny Research Institute (Melanoma/NSCLC) - Pittsburgh
Texas
- M.D. Anderson Cancer Center (Melanoma/NSCLC) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
What NCT06060613 shows while recruiting
NCT06060613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower).
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which OBX-115 is the first listed.
NCT06060613 lists 9 locations in 7 states (California, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT06060613 about?
NCT06060613 is a clinical study titled "Safety and Efficacy of OBX-115 in Advanced Solid Tumors". This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
What is the current status of trial NCT06060613?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2023-10-25. Estimated completion is 2028-06-30.
What conditions does trial NCT06060613 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Melanoma, Metastatic Melanoma, Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT06060613?
The interventions under investigation include: OBX-115 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06060613?
This trial is sponsored by Obsidian Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06060613 being conducted?
This trial has 9 study locations across California, Florida, Kentucky, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06060613's enrollment target sits among peer trials
52 330th of 454 higher than 122 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI